The undersigned members of the brain health community write to express our gratitude for the inclusion of $3 million in funding and accompanying report language in support of the Neurology Drug Program at the Food and Drug Administration (FDA) in the Senate Committee’s draft fiscal year (FY) 23 Agriculture, Rural Development, FDA, and Related Agencies Appropriations bill. As the House and Senate work together to negotiate final FY23 appropriations legislation, we strongly encourage you to maintain this critical funding and language, which will help speed the delivery of safe and effective treatments for brain diseases, mental health conditions, and brain injuries.